TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Follow-Up Questions
TELA Bio Inc (TELA) 的本益比是多少?
TELA Bio Inc 的本益比是 N/A
TELA Bio Inc 的 CEO 是誰?
Mr. Antony Koblish 是 TELA Bio Inc 的 President,自 2012 加入公司。
TELA 股票的價格表現如何?
TELA 的當前價格為 1.62,在上個交易日 increased 了 1.94%。
TELA Bio Inc 的主要業務主題或行業是什麼?
TELA Bio Inc 屬於 Health Care 行業,該板塊是 Health Care
TELA Bio Inc 的市值是多少?
TELA Bio Inc 的當前市值是 $64.2
TELA Bio Inc 是買入、賣出還是持有?
據華爾街分析師稱,共有 7 位分析師對 TELA Bio Inc 進行了分析師評級,包括 3 位強烈買入,6 位買入,2 位持有,0 位賣出,以及 3 位強烈賣出